COMPARING THE EFFECTIVENESS OF DEFINED COMBINATION OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS VS. THERAPIES USING DRUGS THAT HAVE RESPECTIVE INTERNATIONAL NONPROPRIETARY NAMES
https://doi.org/10.22328/2077-9828-2017-9-1-77-81
Abstract
Study objective: To compare the effectiveness of two defined combinations of NRTI drugs, i.e. Abakavir + Lamivudine and Zidovudine + Lamivudine and using drugs having respective international nonproprietary names.
Materials and methods: Using the above defined drug combinations and the respective drugs were compared based on retrospective records of their effectiveness.
Results and discussion: ART was discontinued less often by patients who were treated with defined drug combinations compared with those treated with the respective drugs: 10,6% (Abakavir + Lamivudin) vs. 29,7% (Abakavir (INN) and Lamivudine (INN)) and 17,3% (Zidovudin + Lamivudine) vs. 26,5 (Zidovudin (INN) and Lamivudine (INN)). Non-detectable viral loads were achieved more often by patients who were treated with defined drug combinations compared with those treated with the respective drugs: 80% (Abakavir + Lamivudin) vs. 72,8% (Abakavir (INN) and Lamivudine (INN)) and 72,1% (Zidovudin + Lamivudine) vs. 67,7% (Zidovudin (INN) and Lamivudine (INN)).
About the Authors
A. S. Podymova
Sverdlovsk Regional Center for Prevention and Control of AIDS
Russian Federation
Russian Federation
Yekaterinburg
V. V. Zhukov
Sverdlovsk Regional Center for Prevention and Control of AIDS
Russian Federation
Russian Federation
Yekaterinburg
References
1. Cohen C.J., Meyers J.L., Davis K.L. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open, 2013, Vol. 3, pp. e003028. URL:http://bmjopen.bmj.com/content/3/8/e003028, doi: 10.1136/bmjopen-2013-003028.
2. Cohen C.J., Kubota M., Brachman P.S. Abacavir-Lamivudine Once-Daily HIV Assessment (ALOHA) Study Group. Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study. Pharmacotherapy, 2008, Vol. 28 (3), рр. 314–322.
3. Eron J.J., Yetzer E.S., Ruane P.J., Becker S., Sawyer G.A., Fisher R.L., Tolson J.M., Shaefer M.S. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS, 2000, Vol. 14 (6), рр. 671–681.
4. Homar F., Lozano V., Martínez-Gómez J., Oyagüez I., Pareja A., Payeras A., Serrano J., Carratalá C., Casado M.A. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Economics Review, 2012, Vol. 2, рр. 16.
5. Кашеваров А.Б. О рассмотрении обращения: Письмо ФАС России от 09.06.2015 № АК/28644/15. URI: http://docs.cntd.ru/document/420317526 (14.05.2016) [Электронный текст документа].
6. Sax P.E., Meyers J.L., Mugavero M., Davis K.L. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One, 2012, Vol. 7 (2), рр. e31591. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3286454.
7. Нижегородцев Т.В. О государственных закупках антивирусных препаратов, предназначенных для лечения лиц, инфицированных вирусом иммунодефицита человека (комбинированных и монопрепаратов): разъяснительное письмо ФАС от 24.08.2010. URL: http://fas.gov.ru/
8. documents/documentdetails.html?id=880 (20.12.2016).
9. De Jesus E., Herrera G., Teofilo E., Gerstoft J., Buendia C.B., Brand J.D., Brothers C.H., Hernandez J., Castillo S.A., Bonny T., Lanier E.R. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis., 2004, Vol. 739 (7), рр. 1038–1046.
Review
For citations:
Podymova A.S., Zhukov V.V. COMPARING THE EFFECTIVENESS OF DEFINED COMBINATION OF NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS VS. THERAPIES USING DRUGS THAT HAVE RESPECTIVE INTERNATIONAL NONPROPRIETARY NAMES. HIV Infection and Immunosuppressive Disorders. 2017;9(1):77-81. (In Russ.) https://doi.org/10.22328/2077-9828-2017-9-1-77-81
Views:
1082
.png)
Email this article 